Episode 7 – Cell line development with Dr Natasa Skoko, ICGEB & Dr Hugh Graham, MacroGenics
Posted: 12 April 2022 | Drug Target Review | 1 comment
Tune in to this podcast to hear industry experts discuss cell line monoclonality and the emerging methods that can support clonal origin assurance.
This episode of Drug Target Review‘s podcast, in associate with Molecular Devices, covers cell line development and the assurance of monoclonality in cell lines. Featuring expert speakers Dr Natasa Skoko, Group Leader of the Biotechnology Development Unit at the International Centre for Genetic Engineering and Biotechnology and Dr Hugh Graham, Director of Cell Culture Sciences at MacroGenics.
The expert speakers discuss traditional cell line development workflows and the technologies that can aid in monoclonal assurance.
Key learning points:
- Challenges in traditional cell line development workflows
- How automation can aid bioprocessing scientists
- The emerging technologies that can enable monoclonal assurance
- The role of regulation and its impact on cell line development processes and methods
- Where cell line development processes are headed in the future
Don’t miss out on any podcasts from Drug Target Review – sign up here to be notified of new podcast releases!
Biomarkers aren’t just supporting drug discovery – they’re driving it
FREE market report
From smarter trials to faster insights, this report unpacks the science, strategy and real-world impact behind the next generation of precision therapies.
What you’ll unlock:
- How biomarkers are guiding dose selection and early efficacy decisions in complex trials
- Why multi-omics, liquid biopsy and digital tools are redefining the discovery process
- What makes lab data regulatory-ready and why alignment matters from day one
Explore how biomarkers are shaping early drug development
Access the full report – it’s free!
Dr Natasa Skoko is a Group Leader of the BDU at ICGEB and her current interest is focused on development of biosimilars of Trastuzumab, Certolizumab pegol and Liraglutide. She works in close collaboration with the industrial sector by co-ordinating the transfer of know-how for the production of biosimilars to industry with aim to increase local pharmaceutical industries capacities in emerging markets.
Dr Hugh Graham is the Director, Cell Culture Sciences at MacroGenics Inc in Rockville, Maryland where he and his team develop the upstream processes for a broad pipeline of antibody-based therapeutics. His experience includes small biotechs and large pharma companies and has helped develop, launch and manufacture several commercial biologics.
Related topics
Antibodies, Biologics, Biopharmaceuticals, Biosimilar, Cell Cultures, Legal & Compliance, Protein
Related organisations
Molecular Devices
Dr Natasa Skoko & Dr Hugh Graham really has nice points in this episode. I really loved the part where the emerging technologies that can enable monoclonal assurance.
Nice podcast keep it up.